New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

The new weight-loss tablet was developed in a lab and is based on “a type of β2 agonist.” As explained in the news release: ...

Amycretin — a novel obesity treatment that targets both GLP-1 and amylin receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the Danish drugmaker can improve on the data that triggered a jump in ...

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which targets both GLP-1 and amylin receptors to help control blood sugar and ...

Novo Nordisk (NVO) says its novel obesity drug, amycretin, shows promising results with up to 24% of weight loss in a Phase 1/2 trial. Read more here.

Novo Nordisk, the Danish pharmaceutical company behind amycretin — and also the maker of Wegovy and Ozempic — hopes the pill version of amycretin could make weight-loss therapy more accessible, ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular, and massively lucrative in the last few years ...